Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 50 of 116

  1. GCT1046-04

    Genmab A/S

    Malignant Solid Tumors - Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. GCT1046-07

    Genmab A/S

    Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)

    phase 2 small molecule active

    1 trial

  3. GCT1055-01

    Genmab A/S

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

  4. GCT3013-01

    Genmab A/S

    Lymphoma of B-cell origin

    phase 2 small molecule active

    1 trial

  5. GCT3013-02

    Genmab A/S

    Lymphoma of B-cell origin

    phase 2 small molecule active

    1 trial

  6. GCT3013-03

    Genmab A/S

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  7. GCT3014-01

    Genmab A/S

    Relapsed or Refractory Multiple Myeloma (RRMM) Diffuse Large B Cell Lymphoma (DLBCL) Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  8. GDX012

    Takeda

    Leukemia

    phase 2 small molecule terminated

    1 trial

  9. GEICAM/2014-12

    Ningbo Cancer Hospital

    Metastatic breast cancer

    phase 2 small molecule active

    1 trial

  10. GEICAM/2020-08

    Ningbo Cancer Hospital

    Non-resectable locally advanced or metastatic HER2-positive breast cancer

    phase 2 small molecule active

    1 trial

  11. GEM 2301

    Disc Medicine

    Melanoma

    phase 2 small molecule active

    1 trial

  12. GEM 2303

    Disc Medicine

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  13. GEM-2101

    Disc Medicine

    Uveal melanoma

    phase 2 small molecule active

    1 trial

  14. GEMCAD - 2103//MO4

    Disc Medicine

    Squamous cell carcinoma of the anal canal

    phase 2 small molecule active

    1 trial

  15. GEMCAD 2102

    Disc Medicine

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  16. GEMCAD-1802

    Disc Medicine

    Colorectal cancer and metastatic disease limited to the liver with bad prognosis.

    phase 2 small molecule active

    1 trial

  17. GEMCITABINE

    Wuhan Createrna Science and Technology Co., Ltd

    Upper Tract Urothelial Carcinoma. Upper urinary tract transitional cell carcinoma

    phase 2 small molecule active

    1 trial

  18. GEN1042 DP, PEMBROLIZUMAB

    Genmab A/S

    Metastatic Solid Malignant tumors

    phase 2 small molecule active

    1 trial

  19. GEN1047 DP

    Genmab A/S

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

  20. GEN1078 DP

    Genmab A/S

    Malignant solid tumors

    phase 2 small molecule active

    1 trial

  21. GIM35-RIBOSIL

    Fondazione Telethon ETS

    hormone receptor positive, HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  22. GIMEMA ALL2922

    Fondazione Telethon ETS

    Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.

    phase 2 small molecule active

    1 trial

  23. GINECO- CE111b

    Ningbo Cancer Hospital

    Patients with a histilogically confirmed diagnosis of cervical squamous or adenosquamous carcinoma stage IB3 if N>=1 or II to IVA with any N stage according to FIGO 2018 and no evidence of metastatic disease (M0), without any prior anti-cancer treatment.

    phase 2 other active

    1 trial

  24. GINECO-EN203b

    Ningbo Cancer Hospital

    metastatic or recurrent endometrial or ovarian carcinosarcoma

    phase 2 small molecule active

    1 trial

  25. GINECO-OV243b

    Ningbo Cancer Hospital

    Patients with a confirmed diagnosis of ovarian small cell carcinoma.

    phase 2 small molecule active

    1 trial

  26. GINECO-OV244b

    Ningbo Cancer Hospital

    Platinum sensitive recurrent ovarian cancer

    phase 2 small molecule active

    1 trial

  27. GLPG5101

    Lakefront Biotherapeutics NV

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    phase 2 gene therapy active

    1 trial

  28. GM-CT-01

    GALECTIN THERAPEUTICS INC

    Colorectal Cancer

    phase 2 small molecule terminated

    2 trials

  29. GM-CT-01

    GALECTIN THERAPEUTICS INC

    Cancer of the Bile Duct

    phase 2 small molecule terminated

    1 trial

  30. GM-CT-01 plus 5-Fluorouracil

    GALECTIN THERAPEUTICS INC

    Colorectal Cancer

    phase 2 small molecule terminated

    1 trial

  31. GO40516

    Hoffmann-La Roche

    B-cell non-Hodgkin lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  32. GO40554

    Hoffmann-La Roche

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  33. GO42216

    Hoffmann-La Roche

    Advanced liver cancers

    phase 2 small molecule active

    1 trial

  34. GO43075

    Hoffmann-La Roche

    Diffuse Large B-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  35. GO44096

    Hoffmann-La Roche

    Solid Tumors

    phase 2 other active

    1 trial

  36. GO45434

    Hoffmann-La Roche

    Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

    phase 2 other active

    1 trial

  37. GRAALL2014

    Pari Pharma GmbH

    Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)

    phase 2 other active

    1 trial

  38. GS-US-576-6220

    Gilead Sciences Pty Limited

    Non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  39. GS-US-699-7184-01

    Gilead Sciences Pty Limited

    Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  40. GSK4418959

    IDEAYA Biosciences

    Neoplasms, Colorectal

    phase 2 small molecule active

    1 trial

  41. GT719 Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hematological Malignancy (Leukemia- Lymphoma)

    phase 2 mab active

    1 trial

  42. GTAEXS617

    RECURSION PHARMACEUTICALS, INC.

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  43. GTI-2040

    Aptose Biosciences

    Carcinoma, Renal Cell

    phase 2 small molecule completed

    1 trial

  44. GTI-2040

    Aptose Biosciences

    Acute Myeloid Leukemia

    phase 2 mab completed

    1 trial

  45. GVA + HDAC Consolidation & Gilteritinib Maintenance

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  46. GVM±R regimen

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Peripheral T Cell Lymphoma

    phase 2 small molecule active

    1 trial

  47. Gallium Ga 68 Gozetotide

    United Therapeutics Europe Ltd

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  48. Gamma-retroviral vector MP71 MC2 TCR16-3D9

    Disc Medicine

    advanced melanoma or HNSCC

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.